UBC® Rapid is a powerful Doctors-office test (Point-of-Care), for both primary diagnosis and monitoring of bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. It can easily be performed by a nurse or a technician with minimal training and the results are obtained within 10 minutes. Elevated amounts of cytokeratin protein fragments are present in the urine of many individuals with bladder cancer, even at early stages of the disease. UBC® Rapid shall be used for quantitative determination in combination with the POC-reader, concile® Ω100.
– The only quantitative POC test platform for urine based detection of bladder cancer. – Easy and rapid to perform – result within 10 minutes – Works in haematuria
Clinical evaluation UBC® Rapid performs better than urine cytology in many patients due to improved sensitivity and the combination of UBC® Rapid and cytology enables detection of additional tumors as opposed to cytology alone.
TPS® is a tumor activity marker assay used to support prognosis, treatment monitoring, and patient follow-up for various epithelial cancers, including breast, colorectal, ovarian, and prostate cancer.
TPS® measures soluble fragments of cytokeratin 18, which is over-expressed in epithelial cells and particularly in many types of cancer. This information is crucial for early detection of cancer recurrence and the quick assessment of treatment efficacy.
Cytokeratins Most eukaryotic cells have cytoplasmic cytoskeletal structures known as intermediate filaments. The cytoskeletal network is responsible for the mechanical integrity of the cell and it is critical during cellular processes like cell division, motility and cell to cell contacts. At present more than 20 different cytokeratins have been identified, of which cytokeratin 8, 18 and 19 are the most abundant in simple epithelial cells. The cytokeratins are epithelial cell specific and the cytokeratin pattern is usually preserved during the transformation of normal cells into malignant cells.
Clinical evaluation TPS® is a quantitative immunoassay that specifically measures a defined epitope on cytokeratin 18. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum and plasma. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity. By following the patient with repeated assays of TPS® , both during treatment and at follow up, the clinician obtain critical information about the tumor activity during surveillance for early detection of recurrence.
The tumor marker TPS® is a reliable indicator of tumor cell activity particularly useful in patient managementfor different carcinomas. Compared with conventional tumor mass markers, the activity marker TPS® provides the clinician with earlier signals about the course of the disease. TPS® is particularly useful in treatment monitoring and surveillance of patients with epithelial cell carcinomas e.g. breast, prostate and ovarian cancer.
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality worldwide. Patients may suffer from one of two cancer types: Non-Small Cell Lung Cancer (NSCLC), or the less common, Small-Cell Lung Cancer (SCLC).
Cancer biomarkers are effective for prognostic evaluation and monitoring of disease. MonoTotal® is a sensitive and efficient tool for the management of patients with Non-Small Cell Lung Cancer (NSCLC).
With MonoTotal®, physicians receive an early indication of disease status, measured in terms of tumor cell activity rather than more conventional tumor burden measurements. MonoTotal®provides the physician with a reliable monitoring aid for disease progression and treatment in lung cancer patients.
Clinical evaluation MonoTotal® correlates well with tumor cell activity and the extent of the disease. Studies published during the last years shows that MonoTotal®has a strong association with clinical response in patients. MonoTotal®demonstrates high sensitivity in patients with NSCLC, independent of histotype. The overall sensitivity is about 70-75%, at 95% specificity and correlates well with tumor cell activity and the extent of the disease.
MonoTotal® is a quantitative immunoassay that specifically measures defined epitopes on cytokeratin 19, 8 and 18. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity.
Provides knowledge to decision IDL Biotech is a diagnostic company that develops, produces, and markets In Vitro Diagnostic (IVD) tests worldwide for the health care sector. We are active in the fields of oncology and bacteriology through manufacturing of various tumor markers and a rapid Salmonella typhoid test. IDL Biotech AB (publ) is a public company listed on the Swedish equities market place, Spotlight Stock Market
IDLs products enable disease diagnosis and prognosis, control of treatment efficiency, and prolong the interval between more invasive patient examinations.
We are located just outside Stockholm, Sweden, where all company functions, including management, sales & marketing, orders & shipping, R&D, production, and quality assurance can be found.
IDLs products are distributed primarily in Europe and Asia through a network of international business partners.
Our history In 1988, IDL was founded under the name IDL Immuno Develop Lab. 10 years later the company name was changed to IDL Biotech AB (publ). IDL Biotech AB (publ) has been listed on the Swedish equities market place, Spotlight Stock Market, since 1999.